ArticleiScience2025
HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach.Virus research · 2026Review
- Cholesterol metabolism dysregulated by key HBV mutations revealed through multi-omics profiling.iScience · 2026Article
- Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of Systemic Therapies (2020-2025).Liver cancer · 2026Review
- Efficacy and safety of combining TACE with atezolizumab/bevacizumab versus TACE alone: a retrospective propensity score-matched cohort study in HBV-related hepatocellular carcinoma.Frontiers in oncology · 2026Article
- HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management.Frontiers in immunology · 2026Review
- Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess hepatitis B virus (HBV) reactivation, its impact on prognosis, and its management in patients with HBV-related hepatocellular carcinoma (HCC), who received hepatic arterial infusion chemotherapy (HAIC) plus tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and entecavir (HAIC+TKIs+ICIs+entecavir) treatments. Three hundred and seven patients in five centers with advanced HBV-related HCC, who received the quadruple treatment, were included. The HBV reactivation was observed in 44 (14.3%) patients. HBV-DNA level ≥1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.